louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01658423: Maturity and Motor Fitness
Official title: EFFECT OF MATURITY ON SPRINT AND JUMP PERFORMANCES IN ADOLESCENT BOYS.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Fitness
Keywords: pubic hair
sprint velocity
vertical jump height
body composition
maximal voluntary torque
Lead sponsor: National Institute of Fitness and Sports in Kanoya
Sponsor class: OTHER
Collaborators: name: Junior high school
First posted: 2012-08-07
Enrollment: 107
Sex: MALE
Minimum age (years): 156
Maximum age (years): 167
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Junior high school students

Brief summary: The current study examined the effect of maturity on the sprint and jump performances in a single year age group of 13 year old boys.

Detailed description: The investigators examined the issue in adolescent boys (n = 107) aged from 13.0 to 13.9 years. The maturity status was assessed using a self-assessment of stage of pubic hair based on the criteria of Tanner. Body composition and maximal voluntary knee extension torque (KET) were determined using a bioelectrical impedance analyzer and a static myometer, respectively. Sprint velocity was measured by a non-motorized treadmill. Jump height was calculated from the following equation; g × (flight time)2 × 8 × 10-1. The flight time during jumping was measured by a matswitch system.

Eligibility criteria: Inclusion Criteria:

* adolescents

Exclusion Criteria:

* subjects had some diseases and disorders

Primary outcomes:
measure: Body composition
timeFrame: 1 day
Secondary outcomes:
measure: Muscle strength
timeFrame: 1 day
Other outcomes:
Locations:
city: Kokubu
country: Japan
facility: Chosa junior high school
state: Kagoshima
Study officials:
References:
citation: Armstrong N, Welsman JR, Chia MY. Short term power output in relation to growth and maturation. Br J Sports Med. 2001 Apr;35(2):118-24. doi: 10.1136/bjsm.35.2.118.
Clinical trial NCT00175123: Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele
Official title: Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Myelomeningocele
Bladder, Neurogenic
Keywords: Myelomeningocele
Neurogenic Bladder
Intervention
Botulinum A toxin
Oxybutynin
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2005-09-15
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.

Detailed description: Neurogenic bladder is often seen in children with myelomeningocele, tumors in the spinal canal, or a traumatized spinal cord. The majority of the patients have high pressure bladders which can lead to reflux and frequent infections in the urinary tract. Although children experience insufficient bladder emptying, many of them also experience urinary incontinence and have to perform clean intermittent catheterization (CIC). If no intervention is made, the children are at high risk of renal deterioration.

Eligibility criteria: Inclusion Criteria:

* Myelomeningocele
* Neurogenic bladder with untreated leak point pressures \> 40 mmH2O
* Treated with oxybutynin or other parasympatholytics

Exclusion Criteria:

* Acute urinary tract infection
* Compromised neuromuscular transmission

Primary outcomes:
measure: Bladder capacity and pressures: measures from cystometry
timeFrame: at 4 weeks and 6 months
Secondary outcomes:
measure: Urinary continence: score from an incontinence rating scale
timeFrame: 2 days before and 4 weeks and 6 months after
measure: Constipation: score on the Bristol scale
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Urology, Aarhus University Hospital, Section Skejby
state: Aarhus N
Study officials:
affiliation: Department of Urology, Aarhus University Hospital
name: Bettina Jorgensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03920423: Impact Factors to Success Without Posterior Wall Puncture Using Dynamic Approach
Official title: Impact Factors to Success Without Posterior Wall Puncture Using Ultrasound-guided Short-axis Out-of-plane Dynamic Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Radial Artery Catheterization
Ultrasound or Ultrasonography
Ultrasound-guided Short-axis Out-of-plane Dynamic Approach
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2019-04-18
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study is designed to evaluate and validate impact factors to success and complication using ultrasound guided short-axis out-of-plane dynamic approach, and validate the impaction.

Detailed description: The study including two phase: observational phase and validation phase. In observational phase, factors relative to success catheterization without posterior puncture and success in first attempt are evaluated. In validation phase, patients are randomized into different depth group with or without injection of saline. Success without posterior wall puncture, success in first attempt and overall, catheterization time are compared between groups.

Eligibility criteria: Inclusion Criteria:

* requirement of radial arterial catheterization during perioperative period
* within cardiac-vascular disease
* written consent

Exclusion Criteria:

* contraindication to radial arterial catheterization
* abnormal artery evaluated by ultrasonography

Primary outcomes:
measure: success without posterior wall puncture
timeFrame: Through study completion,an average of 5 minutes
measure: success in first attempt
timeFrame: Through study completion,an average of 5 minutes
Secondary outcomes:
measure: success overall
timeFrame: Through study completion,an average of 5 minutes
measure: time needed to catheterization
timeFrame: Through study completion,an average of 5 minutes
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References:
Clinical trial NCT05915923: Effect of Transcranial Magnetic Stimulation on Dynamic Cerebral Autoregulation in Healthy Adults
Official title: Effect of Transcranial Magnetic Stimulation on Dynamic Cerebral Autoregulation in Healthy Adults
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Transcranial Magnetic Stimulation
Keywords: transcranial magnetic stimulation, healthy adults
Lead sponsor: The First Hospital of Jilin University
Sponsor class: OTHER
First posted: 2023-06-23
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of transcranial magnetic stimulation with different stimulation modes ( 1Hz, 10Hz, sham stimulation ) on cerebral autoregulation.

Detailed description: Current studies have shown that repetitive transcranial magnetic stimulation (TMS) can change the excitability of nerve cells, improve intracerebral artery blood supply, and even reduce the degree of neurological impairment in patients with ischemic stroke.Dynamic cerebral autoregulation (dCA), refers to a complex process in which small intracranial arteries contract or relax to maintain relatively stable cerebral blood volume when systemic arterial blood pressure changes, which can predict the prognosis of patients with ischemic stroke. In this study, we hypothesis that TMS provides neuro-protection by means of improving dCA.

Eligibility criteria: Inclusion Criteria:

1. Age≥18 years, \< 60 years, both genders；
2. Willing to participate and sign the informed consent；
3. Bilateral temporal windows were well penetrated;

Exclusion Criteria:

1. Complaints of previous or existing chronic organic diseases ( stroke, Parkinson 's disease, hypertension, diabetes, etc. ), mental diseases ( bipolar disorder, personality disorder, schizophrenia, etc. ), or cognitive impairment;
2. Suffering from infectious diseases in late one month;
3. Pregnancy or breast-feeding;
4. Sleep disorders, anxiety and depression,
5. Alcohol or drug abuse;
6. History of prescription drugs or over-the-counter (OTC) drugs in the past 2 weeks;
7. History of epilepsy or family history of epilepsy;
8. Implants ( stents or metals );
9. Other conditions that the researchers think are not suitable for the project.

Primary outcomes:
measure: The differences of phase difference (PD) at 30 minutes after transcranial magnetic stimulation under different stimulation modes (1Hz, 10 Hz, sham stimulation).
timeFrame: 0-30minutes
Secondary outcomes:
measure: To compare the difference of phase difference (PD) at 1hour, 6hours and 24hours after transcranial magnetic stimulation under different stimulation modes (1Hz, 10Hz, sham stimulation).
timeFrame: 0-1hour; 0-6hours; 0-24hours
Other outcomes:
Locations:
city: Jilin
country: China
facility: The First Hospital of Jilin University
Study officials:
References:
Clinical trial NCT01359423: Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Claudication
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2011-05-24
Enrollment: 89
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: Primary long full coverage stenting is superior to primary short spot stenting in the treatment of long (≥80 mm) femoropopliteal artery lesions.

Study design :

* Prospective, randomized, multi-center study
* A total of 220 subjects with symptomatic peripheral artery disease of lower limbs who meet all inclusion and exclusion criteria will be included.
* Patients will be randomized in a two by two factorial manner according to the strategy of stenting (long versus short stenting) and the additional use of cilostazol. Each randomization of the enrolled subjects will be done 1:1.
* Patients will be followed clinically for 1 year after the procedure.
* Angiographic or CT follow-up will be performed at 1 year.


Eligibility criteria: Inclusion Criteria:

Clinical criteria:

1. Age 20 years of older
2. Symptomatic peripheral artery disease:

   * Moderate or severe claudication (Rutherford category 2 or 3)
   * Critical limb ischemia (Rutherford category 4 or 5)
3. Patients with signed informed consent

Anatomical criteria:

1. Target lesion length ≥80 mm by angiographic estimation
2. Stenosis of more than 50 percent or occlusion of the ipsilateral superficial femoral artery
3. At least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.

Exclusion Criteria:

Clinical criteria

1. Acute critical limb ischemia
2. Severe critical limb ischemia (Rutherford category 6)
3. Major bleeding history within prior 2 months
4. Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel or contrast agents
5. Age \> 85 years
6. Severe hepatic dysfunction (\> 3 times normal reference values)
7. Significant renal dysfunction (Serum creatinine \> 2.0 mg/dl
8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
9. LVEF \< 40% or clinically overt congestive heart failure
10. Pregnant women or women with potential childbearing
11. Life expectancy \<1 year due to comorbidity

Angiographic criteria

1. Previous bypass surgery or stenting of the superficial femoral artery
2. Untreated inflow disease of the ipsilateral pelvic arteries (more than 50% stenosis or occlusion)

Primary outcomes:
measure: The rate of binary restenosis
timeFrame: 12months after the index procedure
Secondary outcomes:
measure: Ankle-brachial index, etc
timeFrame: at 12 months according to the stenting strategy
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT06322823: Direct Thawing of Vitrified Human Blastocyst
Official title: A Pilot Study on Developing a One-step Direct Thawing Method on Human Blastocysts With Transcriptomic and Methylomic Comparison to Conventional Vitrified-thawing Method
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: IVF
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2024-03-21
Enrollment: 116
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: There are more than million frozen embryo transfers around the world each year; a faster, safer, and cheaper method can save a significant amount of money for patients undergoing IVF treatment worldwide.


Eligibility criteria: Inclusion Criteria:

* Patients who are willing to use direct-thawed blastocysts

Exclusion Criteria:

* Patients who are not willing to use direct-thawed blastocysts

Primary outcomes:
measure: blastocysts survival rate
timeFrame: up to 6 months
Secondary outcomes:
measure: ferilization rate
timeFrame: up to 12 months
measure: pregnancy rate
timeFrame: up to 12 months
measure: live birth rate
timeFrame: up to 24 months
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: David Yiu Leung Chan
Study officials:
References:
Clinical trial NCT03815123: Register Kardialer Computertomographie
Official title: Register Kardialer Computertomographie
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Evaluation of CT in Coronary Artery Stenosis
Lead sponsor: Das Radiologische Zentrum
Sponsor class: OTHER
Collaborators: name: Heidelberg University
First posted: 2019-01-24
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects referred for cardiac CT examination by their physician

Brief summary: The aim of this Heidelberg Cardiac CT Registry (Register kardiale Computertomographie) is to assess the diagnostic and prognostic perfomance of cardiac CT exminations in a real-world patient population.

Detailed description: Anthropometric data, medical history and results of the CT examinations are collected in a database in order to adressing various scientific questions.

Eligibility criteria: Inclusion Criteria:

• Subjects referred for cardiac CT examination by their physician

Exclusion Criteria:

• none

Primary outcomes:
measure: coronary CT angiography
timeFrame: 10 years
measure: coronary CT angiography
timeFrame: 10 years
measure: Agreement with other imaging modalities
timeFrame: 10 years
measure: Occurence of MACE
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Radiologische Praxis Heidelberg
state: Baden-Württemberg
Study officials:
References:
citation: Andre F, Fortner P, Emami M, Seitz S, Brado M, Guckel F, Sokiranski R, Sommer A, Frey N, Gorich J, Buss SJ. Factors influencing the safety of outpatient coronary CT angiography: a clinical registry study. BMJ Open. 2022 Aug 8;12(8):e058304. doi: 10.1136/bmjopen-2021-058304.
Clinical trial NCT01284023: Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects
Official title: Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Compartment Syndrome
Keywords: near infrared spectroscopy
acute compartment syndrome
Lead sponsor: J&M Shuler
Sponsor class: INDUSTRY
Collaborators: name: Nonin Medical, Inc
First posted: 2011-01-26
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Uninjured volunteers will be recruited from a pool of uninjured individuals at the principle investigator's practice. Participation will be completely volutnary

Brief summary: Acute compartment syndrome (ACS) is a complication of lower leg trauma that occurs when the pressure inside the leg due to swelling exceeds the body's ability to provide blood to the muscle of the leg. This condition cuts off blood flow to the leg. Left untreated, the condition can result in devastating consequences including complete loss of function of the lower extremity or amputation. Near-infrared spectroscopy (NIRS)-based tissue perfusion monitors are a non-invasive means of continuously monitoring the amount of oxygen in the tissues of an injured extremity. The device utilizes harmless red light to detect the proportion of hemoglobin saturated with oxygen up to 3 cm below the skin surface. The purpose of this study will be to launch the first stages of validation of this device as a diagnostic tool for compartment syndrome, by observing this device in uninjured subjects.


Eligibility criteria: Inclusion Criteria:

* over 18 years old

Exclusion Criteria:

* any current traumatic lower or upper extremity injury
* unwilling or unable to provide written informed consent
* history of any anatomy-altering injury or procedure to the upper or lower extremity

Primary outcomes:
measure: Near infrared spectroscopy
timeFrame: 1 hour
Secondary outcomes:
measure: Skin pigmentation
timeFrame: prior to monitoring
measure: fat depth
timeFrame: prior to monitoring
Other outcomes:
Locations:
city: Athens
country: United States
facility: Athens Orthopedic Clinic, PA
state: Georgia
Study officials:
affiliation: Athens Orthopedic Clinic, PA
name: Michael Shuler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01662323: Study to Improve the Treatment of Patients With Heart Failure by General Practitioners
Official title: Therapy OPtimization Heart Failure Utrecht
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Heart Failure
Keywords: Heart failure, general practitioner, medical therapy, quality of live
Lead sponsor: Julius Center
Sponsor class: OTHER
Collaborators: name: Agis Zorgverzekeringen
First posted: 2012-08-10
Enrollment: 683
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether it is possible to improve the care of general practitioners for patients with heart failure. The investigators try to reach that goal by training the GP's for 90 minutes in uptitrating the recommended medication according the guidelines. After 6 month the investigators ask the patients to fill out a questionary. The investigators ask them about their quality of live.


Eligibility criteria: Inclusion Criteria:

* Do have a general practitioners diagnosis heart failure mentioned twice in the electronical medical file.

Exclusion Criteria:

* Incapacitated patients with a life expectancy of less than 2 months
* Seniles
* Patients who do not speak the Dutch language

Primary outcomes:
measure: proportion recommended medication for patients with heart failure
timeFrame: up to 6 months
Secondary outcomes:
measure: QoL
timeFrame: up to 1 year
Other outcomes:
Locations:
Study officials:
References:
citation: Valk MJ, Hoes AW, Mosterd A, Landman MA, Broekhuizen BD, Rutten FH. Rationale, design and baseline results of the Treatment Optimisation in Primary care of Heart failure in the Utrecht region (TOPHU) study: a cluster randomised controlled trial. BMC Fam Pract. 2015 Oct 7;16:130. doi: 10.1186/s12875-015-0347-1.
citation: Valk MJ, Broekhuizen BD, Mosterd A, Zuithoff NP, Hoes AW, Rutten FH. COPD in patients with stable heart failure in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2015 Jun 26;10:1219-24. doi: 10.2147/COPD.S77085. eCollection 2015.
Clinical trial NCT03873623: The TOGETHER Project - Kidney
Official title: The TOGETHER Project - Transplant Organ Genomics to Help Prevent Rejection in Kidney Transplant Recipients With Realtime Assay Monitoring
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Transplant Rejection
Keywords: Kidney transplant
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-03-13
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Kidney transplant recipients.

Brief summary: Researchers are trying to develop a way to customize immunosuppression treatment, based on the results of a blood test that measures the risk of rejection.


Eligibility criteria: Inclusion Criteria:

* Conventional solitary kidney transplant (ABO compatible, crossmatch negative, not a kidney transplant simultaneously transplanted with another non-renal organ including heart, liver, lung or pancreas)
* Patients who have given informed consent and are willing to comply with the protocol, including the use of their specimens and data for subsequent research.

Exclusion Criteria:

* EBV -seronegative recipient
* ABO incompatible kidney transplants.
* Simultaneous kidney and extra-renal organ transplants including pancreas, liver, heart, lung, bone marrow transplantation, etc or prior recipient of non-renal transplant. Subjects who had previous extra renal transplants may be included in the study.
* Positive crossmatch kidney transplants (T cell crossmatch \>100, B flow cytometric crossmatch \>150).
* Participating in other clinical trials
* Any kidney transplant recipient \< 18 years of age.

Primary outcomes:
measure: To correlate the findings of TruGraf (a peripheral blood RNA signature that has been shown to correlate with rejection in renal allografts) with rejection episodes in renal transplant patients .
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic
state: Arizona
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mark Stegall, MD
role: PRINCIPAL_INVESTIGATOR
References: